KRAS, a frequently mutated oncogene, has been demonstrated to harbor multiple mutant variants. Although KRAS G12C inhibitors have been successfully approved for clinical use, their efficacy remains limited by acquired resistance and narrow patient eligibility. Here, we leveraged the proteolysis-targeting chimera (PROTA...
Shen-Xin Zeng, Yi-Qing Zhao, Yan-Qing Liu et al.· European journal of medicina...· 0 citations
This work designed and synthesized 20 novel KRAS G12D PROTACs based on the MRTX1133 derivative and found that compound VI-1 exhibited significant KRAS G12D degradation activity in PANC-0203 cells, achieving 69% effective degradation at 10 μM.
Lili Jiang, Wenyan Yang, Yan-Qing Liu et al.· European Journal of Pharmace...· 0 citations
A cascaded AI-driven virtual screening pipeline is developed, integrating sequence-based affinity prediction, equivariant deep learning docking (KarmaDock), and geometric rescoring (DeepDock) to identify novel AURKA inhibitor candidates.